Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLS-3021
- Development stage
- Preclinical
- Lead developer
- Kolon Life Science
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
KLS-3021 is an investigational oncolytic virus therapy being developed by Kolon Life Science for the treatment of solid tumors. The therapy utilizes a vaccinia virus-based platform engineered to express three genes—PH-20, sPD1-Fc, and IL-12—to enhance its anti-tumor activity. Mechanistically, KLS-3021 combines interleukin-12 (IL-12) stimulation with programmed death-ligand 1 (PDL1) inhibition to promote immunologic cytotoxicity and stimulate cell death in tumor cells. The drug is administered intratumorally and remains in preclinical development as of late 2024[1][2][3].
02
Targets
IL-12R (Interleukin-12 receptor)CD274 (Programmed cell death protein 1 ligand 1)IL12 (Interleukin-12)
Beyond the preview
Go deeper on KLS-3021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLS-3021.